Status:
COMPLETED
Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Schizophrenia and Disorders With Psychotic Features
Tobacco Use Disorder
Eligibility:
All Genders
18-70 years
Brief Summary
Nicotine dependence is very common among individuals with schizophrenia and schizoaffective disorder. Cotinine is a chemical that is made by the body from nicotine. Measuring levels of nicotine and co...
Detailed Description
Schizophrenic individuals have higher urinary cotinine levels compared to non-schizophrenic individuals with a similar smoking history. This suggests that schizophrenic individuals may absorb higher d...
Eligibility Criteria
Inclusion
- Meets DSM-IV diagnostic criteria for nicotine dependence and possibly schizophrenia or schizoaffective disorder
- Stable on current antipsychotic regimen(s) for participants with schizophrenia or schizoaffective disorder
Exclusion
- At serious risk of suicide, including recent suicidal behavior or attempt within the thirty days prior to study entry
- Current use of clonidine, bupropion, or any other nicotine products (including nicotine patch, gum, inhaler, lozenge or nasal spray)
Key Trial Info
Start Date :
October 1 2003
Trial Type :
OBSERVATIONAL
End Date :
July 1 2004
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00135772
Start Date
October 1 2003
End Date
July 1 2004
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMDNJ - Robert Wood Johnson Medical School
Piscataway, New Jersey, United States, 08854